51Cr-bleomycin, a new oncophilic radiopharmaceutical. II. Scintigraphic diagnosis of malignant neoplasms.
51Cr-bleomycin was used for the scintigraphic detection of tumours and the assessment of the spread of the disease in 20 patients with various malignancies: 7 with Hodgkin's lymphoma, 5 with other malignant lymphomas, 4 cases of cervix carcinoma and 4 other tumours. The scintigraphy was performed using a Toshiba GC 401 gamma camera coupled to an MDSI computer Trinary. Active foci were scored using a semiquantitative scale of 0 to 5. Results of these studies were compared with those of tests similarly carried out with 57Co-bleomycin (in 9 of the cases) and 67Ga-citrate (11 cases); they demonstrated that the properties of 51Cr-bleomycin for scintigraphic detection of neoplastic foci are similar to those of 57Co-bleomycin.
D001761:Bleomycin; D002860:Chromium Radioisotopes; D003037:Cobalt Radioisotopes; D004407:Dysgerminoma / Q000000981:diagnostic imaging; D005260:Female; D005710:Gallium Radioisotopes; D006689:Hodgkin Disease / Q000000981:diagnostic imaging; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging; D008297:Male; D009369:Neoplasms / Q000000981:diagnostic imaging*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D013724:Teratoma / Q000000981:diagnostic imaging; D013736:Testicular Neoplasms / Q000000981:diagnostic imaging; D002583:Uterine Cervical Neoplasms / Q000000981:diagnostic imaging
D002860:Chromium Radioisotopes; D003037:Cobalt Radioisotopes; D005710:Gallium Radioisotopes; D001761:Bleomycin